<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="134636">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT02104479</url>
  </required_header>
  <id_info>
    <org_study_id>EFFU-ASP 2014</org_study_id>
    <nct_id>NCT02104479</nct_id>
  </id_info>
  <brief_title>Diagnostic Accuracy of Pleural Effusion Aspergillosis Biomarker Testing</brief_title>
  <acronym>EFFU-ASP</acronym>
  <official_title>Open Multicenter Diagnostic Study on the Accuracy of Biomarker Testing (Galactomannan (GM), (1-3)-β-D-glucan (BDG), Aspergillus-specific Polymerase Chain Reaction (PCR) Assay) in Pleural Effusion Samples of Immunocompromised Patients With Suspected Invasive Pulmonary Aspergillosis (IPA)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Heidelberg University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Pfizer</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Heidelberg University</source>
  <oversight_info>
    <authority>Germany: University of Heidelberg</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Diagnostic accuracy of biomarker testing (galactomannan (GM), (1
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      A multicentre, open, prospective diagnostic study on the diagnostic accuracy of biomarker
      testing (galactomannan (GM), (1
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>March 2014</start_date>
  <completion_date type="Anticipated">December 2015</completion_date>
  <primary_completion_date type="Anticipated">September 2015</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Observational</study_type>
  <study_design>Observational Model: Cohort, Time Perspective: Prospective</study_design>
  <primary_outcome>
    <measure>Test Sensitivity</measure>
    <time_frame>one year</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">200</enrollment>
  <condition>Invasive Aspergillosis</condition>
  <condition>Pleural Effusion</condition>
  <condition>Immunosuppression</condition>
  <arm_group>
    <arm_group_label>Immunocompromised Patients</arm_group_label>
    <description>Immunocompromised patients with suspected IPA who have Pleural effusions act as the observed study population</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control Group</arm_group_label>
    <description>Patients without Immunosuppression with pleural effusions</description>
  </arm_group>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      only fungal DNA is investigated, no human DNA
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        - Immunocompomised Patients based on the following conditions: prolonged neutropenia &gt; 10
        d, patients after allogeneic stem cell transplantation or solid organ transplantation,
        Patients wth acute leukemia in induction treatment, patients witrh
        graft-versus-host-disease, patients under chronic immunusuppressive therapy such as
        ciclosporin, patients with HIV, patients with chronic steroid treatment,
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  prolonged neutropenia &gt; 10 d, patients

          -  after allogeneic stem cell transplantation or solid organ transplantation,

          -  Patients wth acute leukemia in induction treatment,

          -  patients witrh graft-versus-host-disease,

          -  patients under chronic immunusuppressive therapy such as ciclosporin,

          -  patients with HIV,

          -  patients with chronic steroid treatment

        Exclusion Criteria:

          -  Age &lt; 18 years

          -  missing informed consent

          -  contraindication for pleural centesis
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Dieter Buchheidt, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Universitätsmedizin Mannheim</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Dieter Buchheidt, MD</last_name>
    <phone>0049.621.383.4115</phone>
    <email>dieter.buchheidt@umm.de</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Mark Reinwald, MD</last_name>
    <phone>0049.621.383.4115</phone>
    <email>mark.reinwald@umm.de</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>University Hospital Mannheim</name>
      <address>
        <city>Mannheim</city>
        <state>Baden-Wuerrtemberg</state>
        <zip>68167</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dieter Buchheidt, MD</last_name>
      <phone>0049.621.383.4115</phone>
      <email>dieter.buchheidt@umm.de</email>
    </contact>
    <contact_backup>
      <last_name>Mark Reinwald, MD</last_name>
      <phone>0049.621.383.4115</phone>
      <email>mark.reinwald@umm.de</email>
    </contact_backup>
    <investigator>
      <last_name>Dieter Buchheidt, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Mark Reinwald, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Wuerzburg University Hospital</name>
      <address>
        <city>Wuerzburg</city>
        <state>Bayern</state>
        <zip>97080</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Werner Heinz, MD</last_name>
      <email>Heinz_W@ukw.de</email>
    </contact>
    <investigator>
      <last_name>Werner Heinz, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <reference>
    <citation>Reinwald M, Spiess B, Heinz WJ, Heussel CP, Bertz H, Cornely OA, Hahn J, Lehrnbecher T, Kiehl M, Laws HJ, Wolf HH, Schwerdtfeger R, Schultheis B, Burchardt A, Klein M, Dürken M, Claus B, Schlegel F, Hummel M, Hofmann WK, Buchheidt D. Aspergillus PCR-based investigation of fresh tissue and effusion samples in patients with suspected invasive Aspergillosis enhances diagnostic capabilities. J Clin Microbiol. 2013 Dec;51(12):4178-85. doi: 10.1128/JCM.02387-13. Epub 2013 Oct 9.</citation>
    <PMID>24108612</PMID>
  </reference>
  <verification_date>April 2014</verification_date>
  <lastchanged_date>April 1, 2014</lastchanged_date>
  <firstreceived_date>March 27, 2014</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Heidelberg University</investigator_affiliation>
    <investigator_full_name>Dieter Buchheidt</investigator_full_name>
    <investigator_title>MD</investigator_title>
  </responsible_party>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Aspergillosis</mesh_term>
    <mesh_term>Pleural Effusion</mesh_term>
    <mesh_term>Invasive Pulmonary Aspergillosis</mesh_term>
    <mesh_term>Pulmonary Aspergillosis</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
